Antibody Response After a Single Dose of an AS03-Adjuvanted Split-Virion Influenza A (H1N1) Vaccine in Heart Transplant Recipients
Pandemic influenza caused a wide spectrum of disease in organ transplant recipients. Monovalent adjuvanted H1N1 vaccine became available in Canada and Europe whereas a nonadjuvanted formulation was available in the U.S. This European study showed that only one-third of the vaccinated cohort had seroprotective titers to vaccine. These results are similar to other studies presented in abstract form at the 2011 American Transplant Congress. Studies looking at strategies to improve the immunogenicity of influenza vaccine are needed.